Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

BACKGROUND: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Diluvio, Laura, Piccolo, Arianna, Marasco, Francesco, Vollono, Laura, Lanna, Caterina, Chiaramonte, Barbara, Niolu, Cinzia, Campione, Elena, Bianchi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668119/
https://www.ncbi.nlm.nih.gov/pubmed/33235810
http://dx.doi.org/10.2144/fsoa-2020-0087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668119/
https://www.ncbi.nlm.nih.gov/pubmed/33235810
http://dx.doi.org/10.2144/fsoa-2020-0087

Ejemplares similares